Brief: Travere Therapeutics Provides Corporate Update And 2025 Outlook

Travere Therapeutics

13/01/2025 13:39

Jan 13 (Reuters) - Travere Therapeutics Inc  TVTX.O :
    * TRAVERE THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2025
OUTLOOK
    * SNDA FOR MODIFICATION OF LIVER MONITORING FOR FILSPARI IN
IGAN
ACCEPTED FOR FDA REVIEW ; PDUFA TARGET ACTION DATE OF AUG 28
    * ON TRACK TO PROVIDE REGULATORY UPDATE ON SPARSENTAN IN
FSGS BY
ITS Q4 2024 EARNINGS CALL
    * EXPECTS FISCAL YEAR 2024 NET PRODUCT SALES TO BE
APPROXIMATELY
$227 MILLION

Source text:  ID:nGNX4n2d4x 
Further company coverage:  TVTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))